Blood pressure lowering efficacy of sacubitril/allisartan versus olmesartan in elderly Chinese hypertensive patientsOA
Blood pressure lowering efficacy of sacubitril/allisartan versus olmesartan in elderly Chinese hypertensive patients
Wei ZHANG;Zi-Chen LIU;Qiang WANG;Xiang-Nan ZHOU;Yan LI;Ji-Guang WANG;Jie YAN;Jin ZHANG;Qian GE;Xiao-Hong LU;Wen-Jie XU;Jing-Chao SUN;Sheng-Mei MU;Yan CHEN
Department of Cardiovascular Medicine,Shanghai Institute of Hypertension,National Center for Translational Medici-ne·Shanghai,State Key Laboratory of Medical Genomics,Shanghai Key Laboratory of Hypertension,Ruijin Hospital,Shang-hai Jiao Tong University School of Medicine,Shanghai,ChinaShenzhen Salubris Pharmaceuticals Co.,Ltd.Shenzhen,Gua-ngdong,ChinaShenzhen Salubris Pharmaceuticals Co.,Ltd.Shenzhen,Gua-ngdong,ChinaShenzhen Salubris Pharmaceuticals Co.,Ltd.Shenzhen,Gua-ngdong,ChinaDepartment of Cardiovascular Medicine,Shanghai Institute of Hypertension,National Center for Translational Medici-ne·Shanghai,State Key Laboratory of Medical Genomics,Shanghai Key Laboratory of Hypertension,Ruijin Hospital,Shang-hai Jiao Tong University School of Medicine,Shanghai,ChinaDepartment of Cardiovascular Medicine,Shanghai Institute of Hypertension,National Center for Translational Medici-ne·Shanghai,State Key Laboratory of Medical Genomics,Shanghai Key Laboratory of Hypertension,Ruijin Hospital,Shang-hai Jiao Tong University School of Medicine,Shanghai,ChinaShenzhen Salubris Pharmaceuticals Co.,Ltd.Shenzhen,Gua-ngdong,ChinaDepartment of Cardiovascular Medicine,Shanghai Institute of Hypertension,National Center for Translational Medici-ne·Shanghai,State Key Laboratory of Medical Genomics,Shanghai Key Laboratory of Hypertension,Ruijin Hospital,Shang-hai Jiao Tong University School of Medicine,Shanghai,ChinaDepartment of Cardiovascular Medicine,Shanghai Institute of Hypertension,National Center for Translational Medici-ne·Shanghai,State Key Laboratory of Medical Genomics,Shanghai Key Laboratory of Hypertension,Ruijin Hospital,Shang-hai Jiao Tong University School of Medicine,Shanghai,ChinaDepartment of Cardiovascular Medicine,Shanghai Institute of Hypertension,National Center for Translational Medici-ne·Shanghai,State Key Laboratory of Medical Genomics,Shanghai Key Laboratory of Hypertension,Ruijin Hospital,Shang-hai Jiao Tong University School of Medicine,Shanghai,ChinaShenzhen Salubris Pharmaceuticals Co.,Ltd.Shenzhen,Gua-ngdong,ChinaShenzhen Salubris Pharmaceuticals Co.,Ltd.Shenzhen,Gua-ngdong,ChinaShenzhen Salubris Pharmaceuticals Co.,Ltd.Shenzhen,Gua-ngdong,ChinaShenzhen Salubris Pharmaceuticals Co.,Ltd.Shenzhen,Gua-ngdong,China
《老年心脏病学杂志(英文版)》 2026 (8)
505-514,10
The study investigators were financially supported by the National Natural Science Foundation of China(No.82070432&No.82070435&No.82270469&No.82370426&No.826706-32),the Ministry of Science and Technology(No.2022YFC360-1302&No.2024ZD0527304),Beijing,China,the Shanghai Mu-nicipal Health Commission(No.2024ZZ1028&No.2025ZZ2-020),the Three-year Action Program of Shanghai Municipa-lity for Strengthening The Construction of Public Health Syst-em(GWV-10.1-XK05)Big Data and Artificial Intelligence Ap-plication,Shanghai,China,the Shenzhen Science and Techn-ology Program(No.KQTD20200820151701004),the China Po-stdoctoral Science Foundation(No.2024M762037),the Science and Technology Commission of Shanghai Municipality(No.25010702600)and also financially supported by Salubris Ph-arma(Shenzhen,Guangdong Province,China).All authors had no conflicts of interest to disclose except Dr.Wang reports rec-eiving lecture and consulting fees from Novartis,Omron,Ser-vier,and Viatris.The authors gratefully acknowledge all inve-stigators at the participating centers and all patients for their co-mmitment to the study.Novartis had no role in the design,con-duct,analysis,interpretation,manuscript preparation,or pub-lication of this research.
评论